Skip to main content
Clinical Trials/NCT07042724
NCT07042724RecruitingNot Applicable

PerSonalized nuTrition and physicAl exeRcise Intervention to Enhance earLy-staGe NSCLC ouTcomes: the STARLighT Study

Universita di Verona2 sites in 1 country324 target enrollmentStarted: September 1, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
324
Locations
2
Primary Endpoint
Pathological complete response [for Cohort A]

Study Overview

Brief Summary

The general goal of the STARLighT study is to test whether a structured physical exercise and nutritional intervention significantly impacts clinical outcomes in patients with early-stage lung cancer.

The main questions it aims to answer are:

  • Can structured physical exercise and nutrition intervention positively modify the pathological complete response in patients with early-stage lung cancer undergoing neoadjuvant treatments?
  • Can structured physical exercise and nutrition intervention positively influence disease-free survival in patients with early-stage lung cancer undergoing adjuvant treatments compared to usual care?

This study will recruit two cohorts of patients. Cohort A will accrue patients who are candidates for neoadjuvant treatment and offer the opportunity to participate in a structured physical exercise and nutritional program, lasting the entire period of anticancer treatment.

Cohort B will accrue patients who are candidates for adjuvant treatments. Patients will be randomized to receive 6 months of structured physical exercise and nutritional intervention or standard of care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • age ≥ 18 years.
  • confirmed diagnosis of resectable or resected non-oncogene addicted NSCLC (EGFR, ALK wild-type).
  • stage IB to IIIB.
  • candidate or undergoing systemic treatment.
  • ECOG performance status 0-
  • written informed consent.
  • willingness to use the technology/device specifically developed for patients' monitoring and support within the trial.

Exclusion Criteria

  • evidence in the medical record of absolute contraindications to exercise, nutritional, or psychological intervention [i.e., heart insufficiency; uncertain arrhythmia; uncontrolled hypertension; severe renal dysfunction, bone marrow insufficiency); reduced standing or walking ability; myocardial infarction].
  • indications for or ongoing artificial nutrition support (totally compromised spontaneous food intake).
  • incapacity, or unavailability to consume oral nutritional supplements.

Outcomes

Primary Outcomes

Pathological complete response [for Cohort A]

Time Frame: From enrollment up to an average of 3 months

Defined as a lack of any viable tumor cells after complete evaluation by the local pathologist in the resected lung cancer specimen and all sampled regional lymph nodes.

Quality of life [for Cohort A]

Time Frame: From enrollment up to an average of 3 months

Assessed using the European Organization for Research and Treatment of Cancer Quality of Life and Core Questionnaire (EORTC QLQ C-30). The scale ranges from 0 to 100; higher values correspond to better quality of life.

Disease-free survival [for Cohort B]

Time Frame: From randomization to the end of follow-up at 2-year.

Defined as the length of time from study inclusion to recurrence of disease, assessed with the RECIST 1.1 criteria, or death due to any cause.

Secondary Outcomes

  • Treatment toxicities(From enrollment up to 6 months.)
  • Overall survival(From baseline to the end of follow-up at 2 years.)
  • Overall response rate(From enrollment up to 6 months.)
  • Disease control rate(From enrollment up to 6 months.)
  • Time to treatment discontinuation(From enrollment up to 6 months.)
  • Immuno-inflammatory status(From enrollment up to 6 months.)
  • Functional capacity(From enrollment up to 6 months.)
  • Body mass index(From enrollment up to 6 months.)
  • Muscle mass(From enrollment up to 6 months.)
  • Sleep quality(From enrollment up to 6 months.)
  • Nutritional risk(From enrollment up to 6 months.)
  • Physical activity level(From enrollment up to 6 months.)
  • Distress level(From enrollment up to 6 months.)
  • Anxiety and Depression levels(From enrollment up to 6 months.)
  • Quality of life [for Cohort B](From enrollment up to 6 months.)

Investigators

Sponsor
Universita di Verona
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sara Pilotto

MD, Ph.D

Universita di Verona

Study Sites (2)

Loading locations...

Similar Trials

Exercise and Nutrition on Early-stage... | Clinical Trial